Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
Marc S. Sabatine(Brigham and Women's Hospital), Evan A. Stein(Oncotherapeutics (United States)), Frederick J. Raal(University of the Witwatersrand), Robert P. Giugliano(Thrombolysis in Myocardial Infarction Study Group), Christie M. Ballantyne(Baylor College of Medicine), Robert C. Scott(Amgen (United States)), Dirk Blom(University of Cape Town), Scott M. Wasserman(Amgen (United States)), Jennifer G. Robinson(University of Iowa), Stephen D. Wiviott(Brigham and Women's Hospital), Jason C. Legg(Amgen (United States)), Ransi Somaratne(Amgen (United States)), Michael J. Koren(Jacksonville Center for Clinical Research)
Cited by 1,494
Related Papers
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
|New England Journal of Medicine|2017|9.1k
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes
|New England Journal of Medicine|2007|6.7k
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2018|6.3k
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
|New England Journal of Medicine|2017|6k